Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Open Access
- 16 May 2016
- journal article
- hepatobiliary
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 21 (9), 1113-1120
- https://doi.org/10.1634/theoncologist.2015-0478
Abstract
Background.: Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare beneficiaries with advanced HCC. Materials and Methods.: Patients with advanced HCC diagnosed from 2008 to 2011 were identified from the Surveillance, Epidemiology, and End Results–Medicare database. Eligible patients received initial sorafenib or no therapy and were covered by Medicare parts A, B, and D. Sorafenib use and outcomes were described in this population. Using a propensity score (PS)-matched sample, we compared the effectiveness of sorafenib versus no treatment by Cox proportional hazards and binomial regression, using a landmark requiring all patients to survive ≥60 days after diagnosis. Results.: Of 1,532 patients, 27% received initial sorafenib. Median duration of sorafenib use was 60 days (interquartile range [IQR], 30–107 days), and median survival from first prescription was 3 months (IQR, 1–8 months). In the PS-matched cohort, median survival was 3 months from the 60-day landmark in sorafenib-treated (n = 223) and 2 months in untreated (n = 223) patients (adjusted hazard ratio, 0.95 [95% confidence interval (CI), 0.78–1.16]). Sorafenib was associated with a nonsignificant reduction in mortality at 3 months (44% versus 51%; adjusted risk ratio, 0.88 [95% CI, 0.72–1.07]), but no reduction thereafter. Conclusion.: Survival after sorafenib initiation in newly diagnosed Medicare beneficiaries with HCC is exceptionally short, suggesting trial results are not generalizable to all HCC patients. The downsides of sorafenib use—high drug-related symptom burden and high drug cost—must be considered in light of this minimal benefit.Keywords
Funding Information
- National Cancer Institute (K07CA160722)
- National Institutes of Health
- Building Interdisciplinary Research Careers in Women's Health
- North Carolina Translational and Clinical Sciences Institute (UL1TR001111)
- Integrated Cancer Information and Surveillance System
- UNC Lineberger Comprehensive Cancer Center
- University Cancer Research Fund
This publication has 20 references indexed in Scilit:
- Utilization and Outcomes of Palliative Therapy for Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory DataDigestive Diseases and Sciences, 2010
- Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United StatesHepatology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Insights into different results from different causal contrasts in the presence of effect-measure modificationPharmacoepidemiology and Drug Safety, 2006
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999
- Optimal Matching for Observational StudiesJournal of the American Statistical Association, 1989
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984